Fennec announced four independent studies evaluating PEDMARK (sodium thiosulfate) across multiple patient populations at ASCO 2026, expanding evidence for broader use beyond pediatric patients. The research demonstrates potential to reduce cisplatin-induced hearing loss in adolescent, young adult, and adult cancer patients, addressing a significant survivorship concern.